Woyach, J. A., Awan, F., Flinn, I. W., Berdeja, J. G., Wiley, E., Mansoor, S., . . . Byrd, J. C. (2014). A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood.
Chicago-tyylinen lähdeviittausWoyach, Jennifer A., et al. "A Phase 1 Trial of the Fc-engineered CD19 Antibody XmAb5574 (MOR00208) Demonstrates Safety and Preliminary Efficacy in Relapsed CLL." Blood 2014.
MLA-viiteWoyach, Jennifer A., et al. "A Phase 1 Trial of the Fc-engineered CD19 Antibody XmAb5574 (MOR00208) Demonstrates Safety and Preliminary Efficacy in Relapsed CLL." Blood 2014.
Varoitus: Nämä viitteet eivät aina ole täysin luotettavia.